Back to Authors

Begna, Kebede

A5011420095 | I1330342723

Mayo Clinic

Citations 27

TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9798-9799

10.1182/blood-2022-165859

Patterns of Lymphoproliferative Disorders in Ethiopia, Based on Single-Center Experience

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12137-12138

10.1182/blood-2022-168012

Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1286-1287

10.1182/blood-2022-165491

Monocytopenia As an Adverse Prognosticator in Vexas Syndrome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 11406-11407

10.1182/blood-2022-165706

Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53therapy-Related Myeloid Neoplasm Patients with Poor Outcome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6964-6965

10.1182/blood-2022-168349

A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 Trial

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1011-1013

10.1182/blood-2022-163436

Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6912-6914

10.1182/blood-2022-170641